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Background: An Expert Forumwas held at the 2014 European Respiratory Society International Congress
to address issues involved in the management of Pseudomonas aeruginosa infection in patients with non-
cystic ﬁbrosis bronchiectasis (NCFB). Multiple studies have found that chronic P. aeruginosa infection is
associated with more severe disease and higher morbidity and mortality.
Overview: Participants discussed appropriate management of P. aeruginosa infection at three stages: 1)
ﬁrst isolation, including eradication protocols; 2) during exacerbations; and 3) during chronic infection,
including long-term antibiotic therapy to reduce the severity of symptoms and frequency of exacerba-
tions. Topics covered included frequency of sputum cultures, antibiotic treatment at ﬁrst isolation and for
exacerbations, optimal use of inhaled antibiotics, indications for long-term therapy, and treatment
regimens that may reduce the frequency or severity of symptoms. Electronic polling and roundtable
discussions followed by expert insights were used to address these topics. Signiﬁcant diversity in
management practices was reported among different countries and centres, and in many cases clinical
management was at variance with published guidelines.
Conclusions: This Expert Forum identiﬁed standardised terminology, clinician training, additional
research into management strategies, and the development of new drugs as areas requiring improve-
ment for the optimal management of P. aeruginosa in NCFB.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Non-cystic ﬁbrosis bronchiectasis (NCFB) is a chronic respiratory
disease characterised by chronic cough, sputum production,
recurrent infection, and sometimes fatigue and haemoptysis. Pa-
tients with NCFB may have functional limitations due to reduced
lung function, bronchial inﬂammation, and airway obstruction
[1,2]. As the disease progresses, NCFB patients frequently experi-
ence signiﬁcant morbidity, reduced quality of life, and high treat-
ment burdens [2e4]. NCFB is associated with high mortality rates.
In a recent study in Belgium, overall mortality was 20% during a 5-
year period [5], and the mortality rate in England and Wales is
reported to be increasing by 3% per year [6]. The prevalence of NCFB
is higher in women and in older individuals and appears to be
increasing over the last decade in Europe and the United States
[4,7e9]. Estimates based on data from the CPRD-GOLD database in
the UK indicate that more than 1% of individuals 70 years of age and
older have NCFB [7]. NCFB has diverse aetiology and this variability
may affect management [3,10].
Although the pathophysiology of NCFB is not well deﬁned, the
vicious cycle model originally proposed by Cole [11], in which
bacterial infection drives airway inﬂammation and disease pro-
gression, has been supported by numerous studies (reviewed by
Mandal and Hill) [12], including a study by Chalmers et al.
demonstrating that high bacterial loads in the airways of patients
with NCFB are associated with markers of local and systemic
inﬂammation [13]. Although a number of bacteria are associated
with NCFB, Pseudomonas aeruginosa is one of the most common
and signiﬁcant pathogens in patients with this disease [14e16]. The
presence of P. aeruginosa is associated with greater impairment in
lung function [17e22], increased airway inﬂammation [13], more
frequent exacerbations [16], worse quality of life [22], greater risk
of hospitalisation [22,23], and increased mortality [5,23,24]. The
impact of Pseudomonas on the natural course of the disease has
been conﬁrmed by its identiﬁcation as a key determinant of
bronchiectasis severity in two recently developed severity scoring
systems, the Bronchiectasis Severity Index and the FACED score
[23,25]. Accordingly, appropriate management of P. aeruginosa is an
important concern throughout the course of NCFB.
In clinical practice, there are three distinct points that present
opportunities for managing P. aeruginosa infection in patients with
NCFB: (1) at ﬁrst isolation; (2) during exacerbations; and (3) during
chronic P. aeruginosa infection (Fig. 1).There are limited data available to inform clinicians on optimal
management at each point, and both national audit and anecdotal
reports suggest that there is signiﬁcant variation among practices
[26].
To better understand current clinical practices for the manage-
ment of P. aeruginosa in patients with NCFB, an Evening Expert
Forum was held during the 2014 European Respiratory Society In-
ternational Congress in Munich, Germany. This interactive seminar
included an international group of practicing clinicians with a
common interest in NCFB. Most (64%) of the 55 participants were
from Europe, but other areas of the world, including Africa (5%),
Asia (7%), Australia (7%), the Middle East (7%), South America (7%),
and the United States (5%), were also represented. Of the 47 par-
ticipants who responded to additional questions, 64% saw patients
as part of a general respiratory clinic, 32% saw patients at a dedi-
cated bronchiectasis clinic, and 4% saw patients as part of a cystic
ﬁbrosis (CF) clinic. These participants reported a wide variation in
the estimated number of NCFB patients seen per year, ranging from
<10 for 9% of participants to >50 for 32% of participants.
Following a case presentation of a common scenario seen in an
NCFB patient with recurring P. aeruginosa infection, a number of
questions were posed and electronic “live” polling was used to
capture responses. The clinicians divided into three groups, each
focusing on one of the three points described above, for roundtable
discussions. Moderators presented the conclusions from each
group, followed by expert feedback.
The ensuing discussion provided an overview of the diversity in
clinical opinion among different centres and countries and offered
an opportunity for expert feedback on current clinical practices
(Table 1).
In addition, the Expert Forum identiﬁed an unmet need in the
medical community for more comprehensive clinical guidelines on
this topic, such as those that are being developed by the European
Respiratory Society Bronchiectasis Guidelines Task Force [29].
Finally, areas requiring future research were discussed, with an
emphasis on the need for standardised deﬁnitions ewhich remain
an area of debate [30] e and practices in NCFB clinical research and
an international registry to allow advancement of the knowledge
base and accurate translation to clinical practice.
2. Management of P. aeruginosa infection at ﬁrst isolation
Much of the clinical practice involved in managing P. aeruginosa
Fig. 1. Intervention points in managing P. aeruginosa respiratory infection in patients with non-cystic ﬁbrosis bronchiectasis. Adapted with permission from ﬁgure by Dr. Patrick
Flume (Medical University of South Carolina, Charleston, South Carolina, USA).
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there are limited data to guide NCFB practitioners [2,31]. In CF, it is
clearly established that early infection with P. aeruginosa is asso-
ciated with worse outcomes (reviewed by Stuart et al.) [32], and
eradication is associated with clinical beneﬁts, including improved
pulmonary function and reduced hospitalisation [33e36]. Accord-
ingly, sputum cultures for CF patients are screened for P. aeruginosa
on a regular basis; European guidelines recommend that airway
cultures be obtained at every visit [37]. For NCFB, the beneﬁts and
feasibility of early P. aeruginosa eradication attempts are still
debated, as this patient population may have been colonised with
this pathogen for extended periods of time before initial detection,
and the frequent presence of comorbid conditions may complicate
management decisions. In addition, although spontaneous clearing
of Pseudomonas infection in CF is considered an unusual event,
intermittent isolation of P. aeruginosawith spontaneous clearing of
the infection (as judged by sputum culture) is not considered un-
common in NCFB. In a recent study of Pseudomonas persistence in
patients with NCFB, 16 of 47 patients (34.0%) who were colonised
with P. aeruginosa (deﬁned as isolation on 2 or more occasions, at
least 3 months apart, within a 1-year period) subsequently became
culture negative during follow-up without any speciﬁc eradication
treatment [20].2.1. Sputum cultures
Signiﬁcant diversity in clinical practice patterns for monitoring
sputum cultures in patients with NCFB was revealed during this
meeting (Fig. 2).
In electronic polling responses to the question “How often do
you send sputum for culture?” 42% of clinical practitioners reported
that they send a sample to the lab at every outpatient visit, in
keeping with the Spanish Society of Pulmonology and Thoracic
Surgery (SEPAR) recommendations that sputum cultures be ob-
tained at each check-up [27]. The second most common answer
(32%) was “only during an exacerbation.” The experts noted that
obtaining sputum cultures only during an exacerbation may impair
the effective use of past microbiology to guide empiric treatment.
Eight percent of participants chose once yearly, but the experts
recommended that this frequency be used only in extremely stable
patients.
Roundtable discussions onmanagement following ﬁrst isolationof P. aeruginosa emphasised the need for a high-quality sputum
sample, obtained during physiotherapy if possible. The potential
need for more sensitive methods for P. aeruginosa identiﬁcation,
such as molecular tests, was also discussed. Participants felt that if
ﬁrst isolation did prove to offer the best chance of eradication, as is
the case for CF, then more sensitive methods of P. aeruginosa
identiﬁcation would be important in facilitating early detection.
Discussion focused on a recent study which found that standard
culture methods only detect about one-third of samples identiﬁed
as positive for P. aeruginosa by molecular methods [16]. The expert
panel noted, however, that the presumed beneﬁts of more sensitive
detection methods are based on the assumption that molecular
methods and culture results represent different positions on the
same clinical continuum, and this hypothesis is yet to be proven.
The key information derived from the sputum sample was
qualitative in nature, namely pathogen identiﬁcation. The round-
table participants did not consider quantitative information (e.g.,
colony counts) to be relevant to treatment choices. Antibiotic sus-
ceptibility tests were generally performed for the ﬁrst isolation of
P. aeruginosa, but not necessarily for routine chronic infections.2.2. Concept of P. aeruginosa eradication
Although European CF guidelines support eradication protocols
for ﬁrst isolation of P. aeruginosa [37,38], the evidence base for NCFB
is less clear. As a result, there were differing opinions at this Expert
Forum concerning whether P. aeruginosa eradication attempts at
ﬁrst isolation are achievable or useful. One expert noted that the
concept of “ﬁrst isolation” was a difﬁcult one in this older popu-
lation, and heavily dependent on the frequency of testing and ac-
curacy of the lab results. This observation highlights the
importance of the signiﬁcant variance in the frequency of obtaining
cultures revealed in earlier discussion.
Although data in NCFB are limited, a recent study suggests that
eradication of P. aeruginosa in NCFB patients may be associated
with improvements in health in some patients. This single-centre
retrospective study involved 30 NCFB patients and found that
eradication protocols were initially successful in 80%. However,
approximately half of these patients had subsequent positive
P. aeruginosa cultures at a median of 6.2 months after eradication.
Patients treated with eradication protocols had a reduced fre-
quency of exacerbations in the year following eradication, but there
Table 1
Management of P. aeruginosa in patients with non-cystic ﬁbrosis bronchiectasis.
Stage Question Guidelines [1,27] Current clinical practicea Expert panel comments
First isolation How often do you send sputum
samples to culture?
 BTS: Respiratory tract specimens
should be obtained in all patients;
frequency not speciﬁed
 SEPAR: Cultures should be performed
at every check-up
 At every visit (42%)
 During an exacerbation (32%)
 When the sample is purulent (18%)
 Once a year (8%)
 Awaiting culture results
during exacerbations may
delay commencement of
empiric antibiotic directed by
prior surveillance
microbiology
 Once yearly cultures should
be reserved for patients with
very stable disease
Should P. aeruginosa
eradication be attempted?
 BTS: There are no studies to guide
practice, but “an attempt to
eradicate seems pragmatic”
 SEPAR: An eradication attempt is
desirable to delay chronic
colonisation
 Most clinicians attempt eradication
at ﬁrst isolation, but the approach to
therapy varies
 Some clinicians did not consider
eradication to be a viable option and
so were more focused on reducing
symptoms than on eradicating
P. aeruginosa
 “First isolation” may be
misleading, as initial sputum
culture may not represent
the ﬁrst appearance of
P. aeruginosa in a patient
 A clinical trial is required to
determine whether
eradication is achievable and
associated with clinical
improvements
What treatment do you use for
P. aeruginosa eradication?
 BTS: Oral ciproﬂoxacin for 2 weeks; if
further treatment required, 2 weeks
of IV anti-pseudomonal antibiotics,
nebulised colistin for 3 months, or
nebulised colistin for 3 months with
an additional 4 weeks of oral
ciproﬂoxacin
 SEPAR: 3 weeks of oral ciproﬂoxacin
plus an inhaled antibiotic, which is
continued for up to 12 months
 Oral ciproﬂoxacin (most common
choice)
 IV antibiotics
 Oral or IV antibiotic þ inhaled
antibiotic
 Other combination therapy
 Expert experience with
guideline-recommended
regimens varied with no evi-
dence for clear superiority of
a speciﬁc regimen in clinical
practice
 Clinical trials are needed to
address the best regimens
for P. aeruginosa eradication
in NCFB [28]
During an
exacerbation
How do you deﬁne an
exacerbation?
 BTSb: Acute deterioration with
increased sputum volume or change
in viscosity, increased sputum puru-
lence, and worsening local symptoms
(increased cough, wheeze, breath-
lessness) or systemic upset
 SEPAR: Acute development and
persistence of changes in sputum
characteristics and/or increased
breathlessness unrelated to other
causes
 No overall consensus
 Symptoms were the most frequent
criteria for deﬁning an exacerbation;
some required 2 or more
 Other deﬁnitions were based on
pulmonary function tests or culture
results
 Expert practice is generally
consistent with guidelines
 Pulmonary function tests and
culture results may not
accurately reﬂect
exacerbations, as some
patients have only minimal
change in FEV1 during an
NCFB exacerbation and well
patients may have chronic
bacterial colonisation
How often do you perform
sputum cultures/susceptibility
tests during an exacerbation?
 BTS and SEPAR: Sputum cultures
with susceptibility tests should be
performed for each exacerbation
prior to administration of antibiotics
 Consistent with guidelines
 Cultures usually repeated 4e8 weeks
after treatment
 Expert practice is consistent
with guidelines
What antibiotics do you use to
treat a patient with
P. aeruginosa and
exacerbations?
 BTS: Oral ciproﬂoxacin (14-day
course of 500 mg or 750 mg twice
daily depending on severity of infec-
tion) for ciproﬂoxacin-susceptible
P. aeruginosa; ciproﬂoxacin-resistant
isolates should be treated with com-
bination therapy with anti-
pseudomonal antibiotics
 SEPAR: Oral ciproﬂoxacin (14- to 21-
day course of 750 mg twice daily) for
mild exacerbations; combination
therapy with anti-pseudomonal an-
tibiotics should be used for moderate
to severe exacerbations or patients
who do not respond to oral therapy
 For ciproﬂoxacin-susceptible strains:
generally oral ciproﬂoxacin
 For ciproﬂoxacin-resistant strains: no
consensus. Options included azi-
thromycin, ciproﬂoxacin, nebulised
colistin, and outpatient IV antibiotics
 Patients with severe exacerbations
are generally hospitalised and
treated with 2 anti-pseudomonal
drugs (beta-lactam or 3rd-generation
cephalosporin þ aminoglycoside);
therapy is modiﬁed on the basis of
clinical response on day 3
 Ciproﬂoxacin-resistant
isolates pose a dilemma: it
can be difﬁcult to ascertain if
culture-determined resis-
tance is clinically relevant, or
if P. aeruginosa is the only
pathogen involved. Accord-
ingly, oral ciproﬂoxacin is a
viable option for initial ther-
apy, followed by IV antibi-
otics if the patient does not
respond clinically
 It is speculated that even
antibiotics without direct
activity against P. aeruginosa
may result in clinical
improvement by affecting
the “microbiome” or
reducing inﬂammation
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Table 1 (continued )
Stage Question Guidelines [1,27] Current clinical practicea Expert panel comments
How do you use inhaled
antibiotics during
exacerbations in patients with
P. aeruginosa infections?
 BTS: Inhaled antibiotics are a possible
component of second-line
combination therapy
 SEPAR: Inhaled antibiotics are not
listed as an option for treatment of
exacerbations
 No consensus on the optimal use of
inhaled antibiotics. Scenarios for
usage included:
 As continuation therapy after
hospital discharge or outpatient
treatment with oral or IV
antibiotics
 Mild exacerbations
 As part of combination therapy for
severe exacerbations
 Ciproﬂoxacin-resistant
P. aeruginosa
 In the experience of the
expert panel, patients tend
to tolerate inhaled antibiotics
better than the literature
suggests; nevertheless,
inhaled antibiotics are
probably best used as
continuation therapy
following oral or IV
antibiotics rather than as
acute therapy
How do you evaluate treatment
success?
 BTS and SEPAR: Not addressed  Based on improvement in symptoms
and inﬂammatory markers
 Reliable, validated markers of
treatment outcome are
required to evaluate
treatment success and
develop new therapies
Chronic
infection,
including
long-term
antibiotic
therapy
What is the deﬁnition of
chronic infection?
 BTS: No deﬁnition speciﬁed
 SEPAR: 3 or more positive cultures of
the same microorganism within 6
months in samples collected at least 1
month apart
 Deﬁnitions varied; most common
were:
 50% of sputum samples positive for
P. aeruginosa
 2 to 3 consecutive positive sputum
cultures following an attempt at
eradication
 Clinical trials vary with
respect to deﬁnition of
chronic infection; this term
should be standardised
Which patients are candidates
for long-term antibiotic
therapy?
 BTS: Should be considered in patients
having 3 exacerbations/year
requiring antibiotic treatment or
patients with fewer exacerbations
that are causing signiﬁcant morbidity
 SEPAR: Should be considered in
patients with recurrent
exacerbations, early relapse,
hospitalisation, declining lung
function, or chronic Pseudomonas
infection
 Varying criteria, including:
 Patients on optimal therapy with a
high burden of symptoms
 Patients who had been
hospitalised, were older, or
reported feeling more unwell
 Generally >3 exacerbations/year
(30% of participants would
consider long-term therapy after 2
exacerbations/year)
 Expert practice is generally
consistent with guidelines
 Some considered >2
exacerbations per year as an
indication for long-term an-
tibiotics
What are the best options for
long-term antibiotic therapy in
patients with chronic
P. aeruginosa infection?
 BTS and SEPAR: An inhaled antibiotic
should be ﬁrst-line therapy for pa-
tients with chronic Pseudomonas in-
fections in patients who meet criteria
for long-term therapy
 BTS: Long-term oral ciproﬂoxacin is
not recommended due to concerns
with resistance and potential side
effects
 Macrolide (76%)
 Inhaled aminoglycoside (24%)
 Others:
 Nebulised colistin
 Oral ciproﬂoxacin
 Combination therapy for
ciproﬂoxacin-resistant
P. aeruginosa
 Treatment was usually administered
as continuous therapy rather than
alternating drugs ormonth on/month
off regimens
 Anti-pseudomonal inhaled
antibiotic preferred,
consistent with guidelines
 The expert panel
acknowledged that
macrolides worked well as
chronic therapy, but
expressed concerns about
resistance development
(especially in NTM) and side
effects
 There is currently no
evidence to support
alternating or month on/
month off regimens in NCFB
Which outcome measures do
you use to evaluate the success
of long-term antibiotic
therapy?
 BTS and SEPAR: Not addressed  Symptomatic improvement,
including reduction in the number
of exacerbations
 Improvement in lung function
 Culture-based results do not factor
into the assessment of outcome
 Reliable, validated markers of
treatment outcome are
required to evaluate
treatment success and
develop new therapies
What is the optimal duration of
long-term antibiotic therapy?
 BTS: Not addressed
 SEPAR: Depends on how well the
infection is controlled
 3 months for eradication protocol or
following IV antibiotics
 1 year or longer for patients with
more severe disease
 Some clinicians take patients off
therapy during the spring or
summer, or cycle therapy during the
year
 Not yet addressed in clinical
trials
 No hard and fast rules;
decisions are often driven by
patient symptoms and
preferences
BTS, British Thoracic Society; FEV1, forced expiratory volume in 1 s; IV, intravenous; NCFB, non-cystic ﬁbrosis bronchiectasis; NTM, non-tuberculous mycobacteria; SEPAR,
Spanish Society of Pulmonology and Thoracic Surgery.
a Percentages are based on polling results; qualitative summaries are based on presentations of roundtable summaries.
b The BTS deﬁnition is speciﬁcally for an exacerbation requiring antibiotics.
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Fig. 2. Respondents’ responses to the question “How often do you send sputum for
culture?” in live electronic polling.
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suggest some beneﬁt from eradication protocols, randomised
clinical trials with larger patient populations will be required to
determine the outcomes associated with P. aeruginosa eradication
following ﬁrst isolation in NCFB patients. Although the participants
generally believed that such trials would be justiﬁable and valuable,
they agreed there would be signiﬁcant practical difﬁculties in
conducting these studies.
2.3. Treatment options including eradication protocols
Treatment of P. aeruginosa following ﬁrst isolation varied
signiﬁcantly among clinicians at this Expert Forum. This diversity
reﬂected differing local guidelines and opinions on the feasibility of
eradication as well as the lack of a clearly preferred eradication
protocol for CF. In a recent Cochrane review of CF therapies used for
P. aeruginosa eradication, various treatment regimens with inhaled
antibiotics (colistin or tobramycin), with or without oral cipro-
ﬂoxacin, appeared to have comparable efﬁcacy, although some of
the studies were underpowered to show a difference between
therapies [40].
Many of the roundtable participants use oral ciproﬂoxacin for
P. aeruginosa eradication therapy in NCFB patients. However, more
aggressive strategies, such as combination therapy with oral or
intravenous (IV) antibiotics, sometimes with the addition of
inhaled antibiotics, were also employed by the participants. The
SEPAR guidelines recommend eradication of P. aeruginosa with 3
weeks of oral ciproﬂoxacin plus an inhaled antibiotic that is
continued for 3e12 months [27]. The British Thoracic Society (BTS)
NCFB guidelines note that although there is no evidence to support
the beneﬁts of eradication, an eradication attempt is a reasonable
intervention; 2 weeks of oral ciproﬂoxacin is the recommended
treatment. If this therapy fails to eradicate Pseudomonas, further
treatment can be considered, such as 2 weeks of IV anti-
pseudomonal antibiotics, nebulised colistin for 3 months, or neb-
ulised colistin for 3 months with an additional 4 weeks of oral
ciproﬂoxacin [1].
Participants reported that they judge the success of treatment
by both sputum cultures and clinical improvement. Sputum cul-
tures are typically performed by participants before and approxi-
mately 4e6 weeks after treatment. Most participants require 2 or 3
negative sputum samples over the next year before they consider
P. aeruginosa to be eradicated. The expert panel agreed with thisdeﬁnition but noted that reliable, validated deﬁnitions of eradica-
tion and treatment outcome are required to evaluate treatment
success and allow the development of new therapies for NCFB [41].3. Management of P. aeruginosa during an exacerbation
Exacerbations are a signiﬁcant complication in patients with
NCFB and are associated with reductions in lung function and
quality of life [19,42]. NCFB patients with P. aeruginosa infections
have more frequent exacerbations and more severe disease
[16,20,23,25]. Accordingly, optimal management of exacerbations
is a critical topic for clinical practitioners with NCFB patients. As
with P. aeruginosa eradication protocols, exacerbation treatment
choices for NCFB often rely on research conducted in CF patients.
However, CF practices have a rather disappointing record of success
in NCFB, and in some cases unexpected adverse events have
occurred [43]. For instance, inhaled tobramycin, an established CF
therapy, was found to result in unexpected pulmonary adverse
events in NCFB patients, including increased cough and wheezing
[44]. Although it is becoming increasingly clear that management
practices for other diseases cannot always be directly transferred to
NCFB, there are few clinical studies available in patients with NCFB
to ﬁll the current knowledge gap.3.1. Deﬁning an exacerbation
Therewas no consensus on how to deﬁne an exacerbation in the
groups assigned to this topic. Most roundtable participants rely
primarily on symptoms, such as increasing sputum volume,
increasing sputum purulence, breathlessness, fatigue, and fever,
and some speciﬁed that they require two or more signiﬁcant
symptoms to classify the event as an exacerbation. Other partici-
pants look at changes in pulmonary function tests or base their
assessment on culture results or radiographs. However, the expert
panel emphasised that pulmonary function tests and culture results
may not accurately reﬂect exacerbations, as in many patients there
is either no change or only minimal change in FEV1 during an NCFB
exacerbation, and well patients may still have chronic bacterial
colonisation.
The BTS guidelines deﬁne an exacerbation requiring antibiotics
as acute deterioration (usually over several days) with all 3 of the
following features: 1) increased sputum volume or change in vis-
cosity; 2) increased sputum purulence; and 3) worsening local
symptoms (increased cough, wheeze, breathlessness) or systemic
upset [1]. The SEPAR guidelines deﬁne an exacerbation as the acute
development and persistence of changes in sputum characteristics
and/or increased breathlessness unrelated to other causes [27].
Clinical trials use a variety of different deﬁnitions for exacerbation,
including a requirement for systemic antibiotics. The expert panel
noted that standardisation of this term would allow different
treatments and management practices to be compared more
accurately across different studies.3.2. Sputum cultures
The roundtable participants concurred that optimal manage-
ment of exacerbations includes a sputum sample with antibiogram
data for each exacerbation prior to administration of antibiotics, in
agreement with BTS and SEPAR guidelines [1,27]. Until this infor-
mation is available, empiric antibiotic therapy is usually guided by
past culture data. Post-exacerbation cultures are usually repeated
approximately 4e8 weeks after treatment.
Fig. 3. Respondents’ choice of treatment for a non-severe exacerbation potentially
associated with ciproﬂoxacin-resistant P. aeruginosa in live electronic polling. The
scenario was presented as: Patient unwell with a chest infection, not severe, sputum
culture one month ago$ Pseudomonas aeruginosa resistant to ciproﬂoxacindwhat
would you prescribe?
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Roundtable participants usually treat patients with mild exac-
erbations and a P. aeruginosa infection known or presumed to be
ciproﬂoxacin-susceptible as outpatients, typically with oral cipro-
ﬂoxacin as recommended by the BTS and SEPAR guidelines [1,27].
BTS guidelines recommend a 14-day course of oral ciproﬂoxacin at
a dose of 500 or 750 mg twice daily depending on the severity of
infection [1], and SEPAR guidelines recommend oral ciproﬂoxacin
at 750 mg twice daily for 14e21 days [27]. It should be noted,
however that these recommendations are based on limited evi-
dence due to the paucity of data from randomised placebo-
controlled trials of antibiotics in NCFB [1].
Patients with more severe exacerbations, such as those with
hypoxaemia or respiratory distress, are often hospitalised, although
some centres operate a home delivery IV antibiotic programme.
Treatment for severe exacerbations varied among participants and
included monotherapy or dual anti-pseudomonal therapy. Most
participants modiﬁed regimens on the basis of clinical response on
the third day of treatment; they agreed that not all patients will
show signs of improvement by this time point, but patients who
have worsened should be changed to an alternative therapy
without further delay. If the clinical response is satisfactory, treat-
ment is continued for at least 10 days. If the clinical response is
suboptimal, the clinicians change antibiotics, usually by opting for a
broader spectrum antibiotic or converting to combination therapy.
The assessment of clinical response is typically based on
improvement in symptoms and blood inﬂammatory markers. The
roundtable participants felt that better markers of treatment
response would be helpful.
Participants usually scheduled post-exacerbation follow-up
visits approximately one month after the event. During this
appointment, they obtain sputum samples and review self-
management of the disease and adherence to treatment. Partici-
pants emphasised the need for effective and clear communication
with the patient and the patient’s primary care physician con-
cerning exacerbation and post-exacerbation management.
Although treatment of ciproﬂoxacin-sensitive isolates was
similar among different centres, there was no consensus on the
preferred option for treatment of ciproﬂoxacin-resistant
P. aeruginosa. Interactive electronic polling was used to explore
the choice of treatment for a patient with a ciproﬂoxacin-resistant
isolate and a non-severe chest infection (Fig. 3).
Dosing and duration of treatment choices were as follows:
ciproﬂoxacin 750 mg bd for 14 days; co-amoxiclavulanate (stan-
dard dose for your country) for 14 days; azithromycin 500 mg od 6
days, then 250 mg od 6 days; colistin nebulised 1 mU bd one
month; outpatient IV antibiotic e.g. ceftazidime 2 g td 10 days;
something else.
The most frequent choice of therapy was azithromycin (23%)
followed by “something else” (21%), but ciproﬂoxacin, nebulised
colistin, and outpatient IV antibiotics were other popular options,
each receiving 15% of the vote. The BTS guidelines recommend
combination antibiotics for patients with P. aeruginosa resistant to
one or more anti-pseudomonal antibiotics [1], and the SEPAR
guidelines recommend combination therapy with IV anti-
pseudomonal antibiotics for patients with severe exacerbations
and those who do not respond to oral therapy [27].
The expert panel noted that ciproﬂoxacin-resistant P. aeruginosa
often represents a conﬂict between therapeutic choices based on
susceptibility results and those based on pragmatic considerations.
Although ciproﬂoxacin-resistant P. aeruginosamay be treated more
effectively with IV antibiotics, it is likely that many patients would
respond to less aggressive treatment options, as in vitro suscepti-
bility ﬁndings do not always translate into clinical response inNCFB. Accordingly, at several centres, the ﬁrst line of treatment for
P. aeruginosa is an oral quinolone, even if the isolate is
ciproﬂoxacin-resistant. Patients who do not respond are switched
to domiciliary IV therapy with anti-pseudomonal drugs.
Another rationale for treating P. aeruginosa exacerbations with
oral antibiotics lacking speciﬁc activity against this pathogen is the
potential effect of the antibiotic on microbiome interactions. Mo-
lecular methods indicate that the NCFB microbiome comprises
multiple potential pathogens with complex interactions [14,45,46].
Unlike more clear-cut models of lung infection, such as pneumonia,
in vitro tests of microbial susceptibility are not necessarily predic-
tive of clinical response [47]. Antibiotic treatment of NCFB patients
is associated with demonstrable reductions in systemic and airway
inﬂammation [13]. It is thus plausible that even antibiotics not
speciﬁcally directed at P. aeruginosa, such as co-amoxiclavulanate
or macrolides could change the microbiome and improve symp-
toms associated with exacerbations.
3.4. Inhaled antibiotics in the treatment of exacerbations
The use of inhaled antibiotics during exacerbations generated
extensive discussion. Compared with oral or IV antibiotics, inhaled
antibiotics reach high concentrations in the airways with reduced
systemic absorption and toxicity [48]. A recent meta-analysis in
patients with NCFB found that 4 weeks of inhaled antibiotics
resulted in an approximately 1000-fold decrease in sputum bac-
terial load and was approximately four times more likely than
placebo to eradicate bacteria from sputum [48]. Participants at the
Expert Forum use inhaled antibiotics in a variety of different ways.
The vast majority use nebulised agents. Some employ these agents
to treat mild exacerbations or as a component of combination
therapy in patients with more severe disease, but others utilise
inhaled therapy only in patients resistant to ciproﬂoxacin. In some
centres, patients are switched to inhaled antibiotics as continuation
therapy upon hospital discharge. The inhaled antibiotic chosen
depended on location and funding considerations. In the BTS
guidelines, inhaled antibiotics are a possible component of 2nd-line
combination therapy (in addition to an IV anti-pseudomonal agent)
for acute exacerbations in patients with P. aeruginosa infection. In
addition, inhaled antibiotics are recommended as 2nd-line therapy
at ﬁrst isolation and as 1st-line therapy for chronic infection with
Fig. 4. Respondents’ responses concerning the number of exacerbations per year
generally required before beginning long-term antibiotic therapy (with inhaled anti-
biotic and/or azithromycin) in live electronic polling.
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otics as an option for treatment of exacerbations, although they are
recommended for initial and chronic infections with Pseudomonas
[27].
There was no clear consensus on the continued use or cessation
of nebulised agents during an exacerbation with signiﬁcant bron-
chospasm, and the participants expressed some concern about the
ability of sicker patients to tolerate inhaled antibiotics. The meta-
analysis of inhaled antibiotics in NCFB reported an overall bron-
chospasm rate of 10% in seven trials involving 526 patients; the use
of inhaled aminoglycosides was associated with a 4.78-fold in-
crease in the risk of bronchospasm, but ciproﬂoxacin and colistin
were not signiﬁcantly associated with this adverse event [48].
However, the expert panel concurred that some patients tended to
tolerate inhaled tobramycin quite well, despite the high rates of
bronchospasm reported in the literature.
3.5. Inhaled antibiotics in the prevention of exacerbations
Two formulations of inhaled ciproﬂoxacin are currently in
development to reduce exacerbations: Ciproﬂoxacin dry powder
for inhalation (DPI) and a liquid combination formulation consist-
ing of a solution of liposomal ciproﬂoxacin mixed with a solution of
un-formulated (free) ciproﬂoxacin. Ciproﬂoxacin DPI is delivered
twice-daily in one to two breaths via a small, hand-held, breath-
actuated inhaler while free/liposomal ciproﬂoxacin is delivered via
nebulisation. Results of Phase III trials will help identify those pa-
tients who may beneﬁt from inhaled forms of the drug in this
scenario [49e52].
4. Management of chronic infection with P. aeruginosa
As discussed previously, chronic colonisation with P. aeruginosa
is associated with more severe disease and worse patient outcomes
[5,20,22,23,25]. Although to date no rigorous clinical data support
the beneﬁts of treating chronic P. aeruginosa infections, there are
strong theoretical reasons for doing so as well as anecdotal evi-
dence from clinical practice [1]. As might be expected from the lack
of data on this topic, there was a wide range of management stra-
tegies for chronic P. aeruginosa infections among the clinicians at
the Expert Forum. Potential therapeutic options for patients with
chronic P. aeruginosa infections are in development (see
clinicaltrials.gov for more information).
4.1. Deﬁning chronic infection
The roundtable participants at this Expert Forum generally
deﬁned chronic infection as at least 50% of sputum cultures positive
for P. aeruginosa over a one year period, or, alternatively, as two to
three consecutive positive sputum cultures following an attempt at
eradication. The SEPAR guidelines deﬁne chronic infection as three
or more positive cultures for the same microorganism within 6
months in samples collected at least 1 month apart [27], while the
BTS guidelines state that varying deﬁnitions exist [1]. The expert
panel noted that there are various deﬁnitions for chronic
P. aeruginosa infection in CF, including the Copenhagen deﬁnition
and the Leeds criteria (reviewed by Pressler et al.) [53], but that
these are based on more frequent sputum cultures (7e10 per year)
and therefore may not be directly applicable to NCFB. Clinical trials
in NCFB differ with respect to criteria for chronic infection, and a
uniform deﬁnition should be established for this term to facilitate
comparisons among research studies and standardise care.
Although increasing levels of antibodies to Pseudomonas are risk
factors and surrogate markers for chronic infection in patients with
CF (reviewed by Presser et al.) [53], the value of monitoring anti-pseudomonal antibodies has not been established for NCFB and
was not commonly performed by the participants.
4.2. Indications for long-term antibiotic therapy
In recognition of the impact of exacerbations on patient well-
being, the BTS guidelines identify reductions in exacerbations as
the aim of chronic management [1]. The roundtable participants
stated that they frequently instituted long-term antibiotic therapy
in patients with NCFB to reduce the frequency and severity of
symptoms, including exacerbations.
The decision to initiate long-term antibiotic therapy in patients
with chronic P. aeruginosa typically depends on the burden of
symptoms. The clinicians considered patients on optimal therapy
(such as physiotherapy and therapy to promote expectoration) who
continue to experience signiﬁcant symptoms, including frequent
exacerbations, a high volume of sputum, purulent sputum, poor
lung function, and fatigue, to be good candidates for long-term
therapy. Other key considerations include hospitalisations, age,
inﬂammatory markers, and the patient’s overall feeling of ill health.
In interactive electronic polling, three exacerbations per year
was the most common threshold required by participants before
initiating long-term antibiotic therapy (46%), although two exac-
erbations was sufﬁcient for 30% of the respondents (Fig. 4).
Together, these data indicate a general threshold of two or more
exacerbations per year for the majority (76%) of respondents. The
BTS guidelines recommend consideration of long-term antibiotics
in patients having three or more exacerbations per year requiring
antibiotic therapy or patients with fewer exacerbations that are
causing signiﬁcant morbidity [1], while the SEPAR guidelines
recommend that prolonged antibiotics therapy should be consid-
ered in patients with recurrent exacerbations, early relapse, hos-
pitalisation, declining lung function, or chronic Pseudomonas
infection [27].
4.3. Long-term antibiotic therapy for patients with chronic
P. aeruginosa infection
Electronic polling was also used to assess the participants’
choice of therapy in patients with chronic P. aeruginosa infection.
When asked whether they generally preferred long-term therapy
with a macrolide, which has been shown to reduce the overall
number of exacerbations [54e56], or with an inhaled antibiotic
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macrolides were chosen by 76% of respondents vs 24% for an
inhaled antibiotic. The preference for macrolides was attributed to
the strong evidence base for the beneﬁt of low-dose chronic ther-
apy with these agents in NCFB [54e56] and the lack of high quality
evidence for inhaled antibiotics. Participants also noted the
simplicity and acceptability of chronic macrolide use [57]. The
choice of macrolide varied among participants and countries due to
availability, cost, and concerns about side effects, including cardiac
toxicity and adverse effects on hearing. Some participants stated
that they are reluctant to institute this therapy in patients with
comorbid cardiac disease. Patients who fail or cannot tolerate
macrolides are typically switched to nebulised colistin or
gentamicin.
In contrast to the preference of participants for macrolides, the
majority of the expert panel preferred an anti-pseudomonal
inhaled antibiotic as long-term antibiotic therapy due to concerns
that thewidespread use of chronic macrolide therapymay promote
resistance to these drugs in the airway microbiota, particularly in
non-tuberculous mycobacteria (NTM) [58]. The experts agreed that
it is imperative to screen patient’s sputum for NTM before
commencing macrolide therapy. Because there are few effective
treatment options for NTM infection, widespread macrolide resis-
tance in NTM could have dire consequences. The BTS and SEPAR
guidelines both recommend an inhaled antibiotic as the ﬁrst option
for patients with chronic Pseudomonas infections whomeet criteria
for long-term antibiotic therapy [1,27].
A recent meta-analysis reported that NTM has an overall prev-
alence of 9.3% in patients with bronchiectasis [59], but some studies
have reported rates as high as 37% [60]. NTM infections frequently
go undetected. In a recent study, 14 of 126 (11%) individuals un-
dergoing lung volume reduction surgery had histological evidence
of mycobacterial infection despite an absence of clinical symptoms
suggestive of NTM [61]. Before initiation of long-term macrolide
therapy, NTM lung disease should be thoroughly screened for and
excluded on the basis of clinical, radiographic, and microbiologic
criteria [62].
Additional choices for long-term antibiotic therapy mentioned
by the participants included oral ciproﬂoxacin or levoﬂoxacin. This
is counter to the BTS guidelines, which caution against the use of
long-term oral ciproﬂoxacin due to the potential development of
antibiotic resistance and adverse events [1].
Inhaled antibiotics might afford a means to overcome bacterial
resistance if the optimal dosing regimen is used [63]. Pharmaco-
kinetic data show that higher concentrations of inhaled vs systemic
ciproﬂoxacin are found in sputum and that the terminal half-life,
clearance and volume of distribution are also greater than previ-
ously reported values for an oral or IV therapeutic dose [64,65]. It is
this increase in drug concentration at the site of infection that is key
to the avoidance of resistance. The lower systemic exposure of
inhaled vs oral formulations is also important when considering
resistance. Oral ciproﬂoxacin is mainly absorbed through the gut
and results in high systemic exposure [66]. This can negatively
impact on gut ﬂora and put selection pressure on non-
Pseudomonal organisms [67]. The peak systemic concentration
measured in healthy volunteers was 0.056 mg/L after Ciproﬂoxacin
DPI 32.5 mg [64], and 0.169 mg/L after administration of one dose
(210 mg ciproﬂoxacin) of the nebulised ciproﬂoxacin mixed
formulation (60 mg as free and 150 mg liposomal ciproﬂoxacin)
[68]. As inhaled antibiotics have low systemic exposure it can be
expected to have a reduced impact on the gut microbiome and
resistance rates. Data from recent and ongoing studies of inhaled
ciproﬂoxacin for the reduction of exacerbations in NCFBwill further
aid understanding of the impact of inhaled ciproﬂoxacin on resis-
tance patterns.4.4. Outcome measures
Success of long-term antibiotic therapy was loosely deﬁned as
“the patient feeling better.” The round table participants agreed
that symptomatic improvements, such as decreased exacerbations,
reduced sputum volume, and improvements in lung function, are
more important in determining the success and continuation of
therapy than culture-based results. The expert panel noted that this
is an area not addressed by guidelines and another term that lacks a
standardised deﬁnition. Recently validated patient-reported as-
sessments of symptoms, such as the Quality of Life Questionnaire-
Bronchiectasis [69,70], may help allow more accurate evaluations
of symptomatic improvements.
4.5. Duration of long-term antibiotic treatment
The roundtable participants typically continue long-term anti-
biotic treatment for approximately 3 months in patients undergo-
ing an eradication attempt or following IV antibiotics, and for a year
or more in patients with more severe disease. Some clinicians
support the patient’s choice of a treatment holiday and take pa-
tients off therapy in the spring or summer months, while others
give the patient 2 or 3 cycles of therapy over the course of the year.
For inhaled agents, continuous therapy was more common than
alternating agents or month on/month off regimens, in contrast to
common practice in CF patients and NCFB clinical trials. Decisions
concerning the duration of chronic treatment are made with the
patient’s input and are often guided by the prevailing seasonality of
respiratory viruses. BTS guidelines do not address the duration of
long-term therapy, while SEPAR guidelines state that it depends on
how well the infection is controlled [1,27].
5. Improving the management of P. aeruginosa in NCFB
On the basis of the roundtable discussions at this Expert Forum,
the attendees concluded that there was a wide variety of ap-
proaches to themanagement of P. aeruginosa in NCFB and a need for
greater international collaboration to ensure appropriate dissemi-
nation of information on this important topic. The roundtable
discussions also highlighted the importance of standardised ter-
minology, including uniform deﬁnitions for eradication, exacerba-
tion, chronic infection, treatment response, and outcomes of long-
term antibiotic therapy. Widely-accepted, common deﬁnitions are
essential so that treatment practices and outcomes can be accu-
rately and rigorously evaluated in clinical trials and compared
among different centres.
The participants also identiﬁed several clinical research ques-
tions that need to be addressed, including:
 Do P. aeruginosa eradication protocols provide long-term ben-
eﬁts to NCFB patients?
 Is culture-directed antibiotic therapy more effective than
empiric therapy during exacerbations?
 Is long-term suppressive antibiotic therapy associated with
increased antibiotic resistance?
 What is the optimal regimen and duration for long-term anti-
biotic treatment regimens?
Although retrospective studies and analyses of bronchiectasis
registries may be able to address some of these research questions,
randomised clinical trials in NCFB will be required for deﬁnitive
answers. The European Multicentre Bronchiectasis Audit and
Research Collaboration (EMBARC), which was created to promote
research and education in the ﬁeld of bronchiectasis, provides a
network that will hopefully encourage and facilitate clinical trials in
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In addition, results from studies of new therapeutic agents will
hopefully broaden available treatment options and provide addi-
tional insights into the effects of therapy on the course of the
disease.
6. Conclusions
This Expert Forum revealed signiﬁcant diversity among
different centres and countries with respect to the management of
P. aeruginosa-infected NCFB patients. These differences are pre-
dominantly driven by the lack of a robust evidence base. Sharing
treatment insights and expert guidance may help improve patient
management. The care of NCFB would be improved by clinician
training on this topic, standardised terminology, and clinical
research designed to address key questions and provide additional
information on the most beneﬁcial therapeutic options.
Note on terminology
Dr. Elborn prefers the use of the designation of Bronchiectasis
rather than non-CF bronchiectasis as discussed in Chalmers and
Elborn, 2015 [30].
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